Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2022

Open Access 01-12-2022 | Research

Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy

Authors: Benoît Sanson, Caroline Stalens, Céline Guien, Luisa Villa, Catherine Eng, Sitraka Rabarimeriarijaona, Rafaëlle Bernard, Pascal Cintas, Guilhem Solé, Vincent Tiffreau, Andoni Echaniz-Laguna, Armelle Magot, Raul Juntas Morales, François Constant Boyer, Aleksandra Nadaj-Pakleza, Agnès Jacquin-Piques, Christophe Béroud, Sabrina Sacconi, The French FSHD registry collaboration group

Published in: Orphanet Journal of Rare Diseases | Issue 1/2022

Login to get access

Abstract

Background

Facioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent muscular dystrophies and currently has no treatment. Clinical and genetic heterogeneity are the main challenges to a full comprehension of the physiopathological mechanism. Improving our knowledge of FSHD is crucial to the development of future therapeutic trials and standards of care. National FSHD registries have been set up to this end. The French National Registry of FSHD combines a clinical evaluation form (CEF) and a self-report questionnaire (SRQ), filled out by a physician with expertise in neuromuscular dystrophies and by the patient, respectively. Aside from favoring recruitment, our strategy was devised to improve data quality. Indeed, the pairwise comparison of data from 281 patients for 39 items allowed for evaluating data accuracy. Kappa or intra-class coefficient (ICC) values were calculated to determine the correlation between answers provided in both the CEF and SRQ.

Results

Patients and physicians agreed on a majority of questions common to the SRQ and CEF (24 out of 39). Demographic, diagnosis- and care-related questions were generally answered consistently by the patient and the medical practitioner (kappa or ICC values of most items in these groups were greater than 0.8). Muscle function-related items, i.e. FSHD-specific signs, showed an overall medium to poor correlation between data provided in the two forms; the distribution of agreements in this section was markedly spread out and ranged from poor to good. In particular, there was very little agreement regarding the assessment of facial motricity and the presence of a winged scapula. However, patients and physicians agreed very well on the Vignos and Brooke scores. The report of symptoms not specific to FSHD showed general poor consistency.

Conclusions

Patient and physician answers are largely concordant when addressing quantitative and objective items. Consequently, we updated collection forms by relying more on patient-reported data where appropriate. We hope the revised forms will reduce data collection time while ensuring the same quality standard. With the advent of artificial intelligence and automated decision-making, high-quality and reliable data are critical to develop top-performing algorithms to improve diagnosis, care, and evaluate the efficiency of upcoming treatments.
Appendix
Available only for authorised users
Literature
2.
go back to reference Flanigan KM, et al. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord. 2001;11(6–7):525–9.PubMedCrossRef Flanigan KM, et al. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord. 2001;11(6–7):525–9.PubMedCrossRef
3.
go back to reference Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83(12):1056–9.PubMedPubMedCentralCrossRef Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83(12):1056–9.PubMedPubMedCentralCrossRef
4.
go back to reference Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet. 2009;75(6):550–5.PubMedCrossRef Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet. 2009;75(6):550–5.PubMedCrossRef
6.
go back to reference Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P, et al. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol. 2016;263:1401–8.PubMedPubMedCentralCrossRef Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P, et al. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol. 2016;263:1401–8.PubMedPubMedCentralCrossRef
7.
go back to reference Padberg GW. Facioscapulohumeral disease. Leiden: Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University; 1982. Padberg GW. Facioscapulohumeral disease. Leiden: Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University; 1982.
8.
go back to reference Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2014;49(4):520–7.PubMedCrossRef Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2014;49(4):520–7.PubMedCrossRef
9.
go back to reference Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology. 1998;50(6):1791–4.PubMedCrossRef Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology. 1998;50(6):1791–4.PubMedCrossRef
10.
go back to reference Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord. 2013;23(4):298–305.PubMedCrossRef Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord. 2013;23(4):298–305.PubMedCrossRef
11.
go back to reference Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology. 2013;80(13):1247–50.PubMedPubMedCentralCrossRef Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology. 2013;80(13):1247–50.PubMedPubMedCentralCrossRef
12.
go back to reference Brouwer OF, Padberg GW, Ruys CJ, Brand R, Grote JJ. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology. 1991;41(12):1878.PubMedCrossRef Brouwer OF, Padberg GW, Ruys CJ, Brand R, Grote JJ. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology. 1991;41(12):1878.PubMedCrossRef
13.
go back to reference Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012;44(12):1370.PubMedPubMedCentralCrossRef Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012;44(12):1370.PubMedPubMedCentralCrossRef
14.
go back to reference Sacconi S, Briand-Suleau A, Gros M, Baudoin C, Lemmers RJ, Rondeau S et al. FSHD1 and FSHD2 form a disease continuum. Neurology. 2019;92(19):e2273–85.PubMedPubMedCentralCrossRef Sacconi S, Briand-Suleau A, Gros M, Baudoin C, Lemmers RJ, Rondeau S et al. FSHD1 and FSHD2 form a disease continuum. Neurology. 2019;92(19):e2273–85.PubMedPubMedCentralCrossRef
15.
go back to reference Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol. 2011;24(5):423–8.PubMedCrossRef Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol. 2011;24(5):423–8.PubMedCrossRef
16.
17.
go back to reference Rodrigues M, Hammond-Tooke G, Kidd A, Love D, Patel R, Dawkins H, et al. The New Zealand neuromuscular disease registry. J Clin Neurosci. 2012;19(12):1749–50.PubMedCrossRef Rodrigues M, Hammond-Tooke G, Kidd A, Love D, Patel R, Dawkins H, et al. The New Zealand neuromuscular disease registry. J Clin Neurosci. 2012;19(12):1749–50.PubMedCrossRef
18.
go back to reference Vercelli L, Mele F, Ruggiero L, Sera F, Tripodi S, Ricci G, et al. A 5-year clinical follow-up study from the Italian National Registry for FSHD. J Neurol. 2021;268:356–66.PubMedCrossRef Vercelli L, Mele F, Ruggiero L, Sera F, Tripodi S, Ricci G, et al. A 5-year clinical follow-up study from the Italian National Registry for FSHD. J Neurol. 2021;268:356–66.PubMedCrossRef
19.
go back to reference Guien C, Blandin G, Lahaut P, Sanson B, Nehal K, Rabarimeriarijaona S, et al. The French National Registry of patients with Facioscapulohumeral muscular dystrophy. Orphanet J Rare Dis. 2018;13(1):218.PubMedPubMedCentralCrossRef Guien C, Blandin G, Lahaut P, Sanson B, Nehal K, Rabarimeriarijaona S, et al. The French National Registry of patients with Facioscapulohumeral muscular dystrophy. Orphanet J Rare Dis. 2018;13(1):218.PubMedPubMedCentralCrossRef
20.
go back to reference Tawil R, van der Maarel S, Padberg GW, van Engelen BGM. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010;20:471–5.PubMedCrossRef Tawil R, van der Maarel S, Padberg GW, van Engelen BGM. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010;20:471–5.PubMedCrossRef
21.
go back to reference Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186–97.PubMedCrossRef Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186–97.PubMedCrossRef
22.
go back to reference Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. JAMA. 1963;184(2):89–96.PubMedCrossRef Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. JAMA. 1963;184(2):89–96.PubMedCrossRef
23.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef
24.
go back to reference Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43:543–8.PubMedCrossRef Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43:543–8.PubMedCrossRef
25.
go back to reference Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43:551–8.PubMedCrossRef Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43:551–8.PubMedCrossRef
26.
27.
go back to reference Lunt PW, Compston DA, Harper PS. Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet. 1989;26:755–60.PubMedPubMedCentralCrossRef Lunt PW, Compston DA, Harper PS. Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet. 1989;26:755–60.PubMedPubMedCentralCrossRef
28.
go back to reference Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol. 1999;45(6):751–7.PubMedCrossRef Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol. 1999;45(6):751–7.PubMedCrossRef
29.
go back to reference Tawil R. Chapter 35 - Facioscapulohumeral muscular dystrophy. In: Geschwind DH, Paulson HL, Klein C, editors. Handb Clin Neurol. Amsterdam: Elsevier; 2018. p. 541–8. Tawil R. Chapter 35 - Facioscapulohumeral muscular dystrophy. In: Geschwind DH, Paulson HL, Klein C, editors. Handb Clin Neurol. Amsterdam: Elsevier; 2018. p. 541–8.
30.
go back to reference van der Sluijs BM, Knoop H, Bleijenberg G, van Engelen BG, Voermans NC. The Dutch patients’ perspective on oculopharyngeal muscular dystrophy: a questionnaire study on fatigue, pain and impairments. Neuromuscul Disord. 2016;26(3):221–6.PubMedCrossRef van der Sluijs BM, Knoop H, Bleijenberg G, van Engelen BG, Voermans NC. The Dutch patients’ perspective on oculopharyngeal muscular dystrophy: a questionnaire study on fatigue, pain and impairments. Neuromuscul Disord. 2016;26(3):221–6.PubMedCrossRef
31.
go back to reference LoRusso S, Johnson NE, McDermott MP, Eichinger K, Butterfield RJ, Carraro E, et al. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurol. 2019;19:224.PubMedPubMedCentralCrossRef LoRusso S, Johnson NE, McDermott MP, Eichinger K, Butterfield RJ, Carraro E, et al. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurol. 2019;19:224.PubMedPubMedCentralCrossRef
32.
go back to reference Sárközy A, Bushby K, Beroud C, Lochmuller H. 157th ENMC international workshop: patient registries for rare, inherited muscular disorders 25–27 January 2008 Naarden, The Netherlands. Neuromuscul Disord NMD. 2008;18:997–1001.PubMedCrossRef Sárközy A, Bushby K, Beroud C, Lochmuller H. 157th ENMC international workshop: patient registries for rare, inherited muscular disorders 25–27 January 2008 Naarden, The Netherlands. Neuromuscul Disord NMD. 2008;18:997–1001.PubMedCrossRef
33.
34.
go back to reference Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007–2013). Contemp Clin Trials. 2015;43:1–9.PubMedCrossRef Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007–2013). Contemp Clin Trials. 2015;43:1–9.PubMedCrossRef
35.
go back to reference Brasil S, Pascoal C, Francisco R, dos Reis Ferreira V, Videira PA, Valadão AG. Artificial intelligence (AI) in rare diseases: is the future brighter? Genes. 2019;10:978.PubMedCentralCrossRef Brasil S, Pascoal C, Francisco R, dos Reis Ferreira V, Videira PA, Valadão AG. Artificial intelligence (AI) in rare diseases: is the future brighter? Genes. 2019;10:978.PubMedCentralCrossRef
36.
go back to reference Yousefi J, Hamilton-Wright A. Characterizing EMG data using machine-learning tools. Comput Biol Med. 2014;51:1–13.PubMedCrossRef Yousefi J, Hamilton-Wright A. Characterizing EMG data using machine-learning tools. Comput Biol Med. 2014;51:1–13.PubMedCrossRef
37.
go back to reference Morrow JM, Sormani MP. Machine learning outperforms human experts in MRI pattern analysis of muscular dystrophies. Neurology. 2020;94:421–2.PubMedCrossRef Morrow JM, Sormani MP. Machine learning outperforms human experts in MRI pattern analysis of muscular dystrophies. Neurology. 2020;94:421–2.PubMedCrossRef
38.
go back to reference Stafford IS, Kellermann M, Mossotto E, Beattie RM, MacArthur BD, Ennis S. A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. npj Digit Med. 2020;3:1–11.CrossRef Stafford IS, Kellermann M, Mossotto E, Beattie RM, MacArthur BD, Ennis S. A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. npj Digit Med. 2020;3:1–11.CrossRef
39.
go back to reference Mul K, Kinoshita J, Dawkins H, van Engelen B, Tupler R, FSHD Consortium. 225th ENMC international workshop: a global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands. Neuromuscul Disord. 2017;27:782–90.PubMedCrossRef Mul K, Kinoshita J, Dawkins H, van Engelen B, Tupler R, FSHD Consortium. 225th ENMC international workshop: a global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands. Neuromuscul Disord. 2017;27:782–90.PubMedCrossRef
Metadata
Title
Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy
Authors
Benoît Sanson
Caroline Stalens
Céline Guien
Luisa Villa
Catherine Eng
Sitraka Rabarimeriarijaona
Rafaëlle Bernard
Pascal Cintas
Guilhem Solé
Vincent Tiffreau
Andoni Echaniz-Laguna
Armelle Magot
Raul Juntas Morales
François Constant Boyer
Aleksandra Nadaj-Pakleza
Agnès Jacquin-Piques
Christophe Béroud
Sabrina Sacconi
The French FSHD registry collaboration group
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2022
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-021-01793-6

Other articles of this Issue 1/2022

Orphanet Journal of Rare Diseases 1/2022 Go to the issue